Filtered By:
Source: American Heart Journal
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Background: The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major cardiovascular (CV) events from the addition of ezetimibe versus placebo to 40 mg/d of simvastatin therapy in patients who present with acute coronary syndromes and have low-density lipoprotein cholesterol (LDL-C) ≤125 mg/dL.Methods: The primary composite end point is CV death, nonfatal myocardial infarction (MI), nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (≥30 days postrandomization). The simvastatin monotherapy arm’s LDL-C target is
Source: American Heart Journal - May 19, 2014 Category: Cardiology Authors: Michael A. Blazing, Robert P. Giugliano, Christopher P. Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald, Robert M. Califf Tags: Acute Ischemic Heart Disease Source Type: research
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy
This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.Methods: This was a double-blind, placebo-controlled, 2 × 2 factorial multicenter randomized trial of 1,708 post–myocardial infarction (MI) patients ≥50 years of age and with creatinine ≤2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitamin-multimineral mixture or placebo. The primary end point was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.Results: Median age was 65 years, 1...
Source: American Heart Journal - April 4, 2014 Category: Cardiology Authors: Gervasio A. Lamas, Robin Boineau, Christine Goertz, Daniel B. Mark, Yves Rosenberg, Mario Stylianou, Theodore Rozema, Richard L. Nahin, L. Terry Chappell, Lauren Lindblad, Eldrin F. Lewis, Jeanne Drisko, Kerry L. Lee Tags: Coronary Artery Disease Source Type: research
